11.1 Critical Illness, Sepsis & Trauma Nutrition

11.1 Critical Illness, Sepsis & Trauma Nutrition

Clinical Core: The systemic response to severe trauma, burn injury, and septic shock is characterized by profound neuroendocrine and metabolic dysregulation. Clinicians must distinguish the initial hypoperfused, hypometabolic Ebb phase (first 24 to 48 hours)—where hemodynamic resuscitation takes absolute precedence over nutrition—from the hyperdynamic, hypercatabolic Flow phase, marked by unsuppressible hepatic gluconeogenesis, extensive skeletal muscle proteolysis, and severe peripheral insulin resistance. According to SCCM/ASPEN critical care nutrition guidelines, early enteral nutrition (EN) should be initiated within 24 to 48 hours of ICU admission once volume resuscitation is established. High-risk patients (NUTRIC score $\ge 5$ or NRS-2002 $\ge 5$) derive the greatest benefit from prompt feeding. In hemodynamic instability, EN is strictly held during active shock (MAP $< 65\text{ mmHg}$ or escalating pressors) due to non-occlusive mesenteric ischemia risk, but trophic feeds may proceed cautiously on low-dose stable vasopressors. Immune-modulating formulas are not recommended routinely in severe sepsis, and supplemental high-dose glutamine should be avoided in multi-organ dysfunction because trials found harm.

---

The Neuroendocrine Stress Response: Ebb, Flow, and Recovery Phases

In 1942, Sir David Cuthbertson first characterized the biphasic systemic response to physical injury, which contemporary critical care medicine categorizes into three distinct physiological periods: the Ebb phase, the Flow (catabolic) phase, and the Recovery (anabolic) phase.

                      [ TRAUMATIC INSULT / SEVERE SEPSIS ]
                                       │
                                       ▼
   ┌───────────────────────────────────────────────────────────────────────┐
   │ 1. EBB PHASE (First 24–48 Hours)                                      │
   │ • Hypovolemic shock, tissue hypoperfusion, cellular hypoxia           │
   │ • Depressed metabolic rate, low VO2, hypothermia, low cardiac output  │
   │ • Neuroendocrine surge: Epinephrine, Norepinephrine, Cortisol, ADH   │
   │ • PRIORITY: Hemodynamic resuscitation; ENTERAL NUTRITION WITHHELD     │
   └───────────────────────────────────┬───────────────────────────────────┘
                                       │ (Fluid & Hemodynamic Resuscitation)
                                       ▼
   ┌───────────────────────────────────────────────────────────────────────┐
   │ 2. FLOW PHASE — CATABOLIC SUBPHASE (Days to Weeks)                    │
   │ • Hyperdynamic cardiovascular state: Tachycardia, high cardiac output │
   │ • Hypermetabolism: Elevated VO2, elevated REE (+20% to +100%)         │
   │ • Unsuppressible hepatic gluconeogenesis & extreme insulin resistance │
   │ • Massive skeletal muscle proteolysis (ubiquitin-proteasome pathway)   │
   │ • PRIORITY: Early EN within 24–48h; high protein; avoid overfeeding   │
   └───────────────────────────────────┬───────────────────────────────────┘
                                       │ (Infection Control & Wound Healing)
                                       ▼
   ┌───────────────────────────────────────────────────────────────────────┐
   │ 3. RECOVERY / ANABOLIC PHASE (Weeks to Months)                        │
   │ • Normalization of hormone levels; inflammatory cytokines dissipate   │
   │ • Restoration of insulin sensitivity; positive nitrogen balance       │
   │ • Tissue repair, muscle rebuilding, physical rehabilitation           │
   └───────────────────────────────────────────────────────────────────────┘

1. The Ebb Phase (Initial 24 to 48 Hours)

• Pathophysiological Derangements: Immediate response to severe burn, hemorrhagic shock, polytrauma, or acute pancreatitis. Manifested by hypovolemia, decreased central venous pressure, systemic hypoperfusion, lactic acidosis, decreased cardiac output, and reduced cellular oxygen consumption ($V_{\text{O}_2}$). Core body temperature and resting energy expenditure (REE) are characteristically depressed.
• Endocrine Drivers: Massive sympathetic nervous system discharge triggers an abrupt surge in catecholamines (epinephrine, norepinephrine), cortisol, renin-angiotensin-aldosterone, and antidiuretic hormone (ADH) to preserve intravascular volume and perfusion to the brain and myocardium.
• Clinical Rule: Enteral nutrition is strictly contraindicated during the Ebb phase. The splanchnic circulation is vasoconstricted; delivering nutrients into an under-perfused gastrointestinal tract triggers bowel distension, non-occlusive bowel ischemia, and transmural necrosis. The sole clinical priority is aggressive volume repletion, surgical hemorrhage control, and restoration of tissue microperfusion.

2. The Flow Phase (Catabolic Stage)

• Pathophysiological Derangements: Commences once volume resuscitation restores macrovascular and microvascular perfusion. Characterized by a hyperdynamic cardiovascular state (high cardiac index, tachycardia, widened pulse pressure), pyrexia, increased systemic oxygen delivery and consumption, and elevated resting energy expenditure (often $20\%\text{ to }50\%$ above baseline, and up to $100\%$ in severe thermal injuries).
• Cytokine and Endocrine Cascades: Sustained by pro-inflammatory cytokines—primarily Tumor Necrosis Factor-alpha ($\text{TNF}-\alpha$), Interleukin-1 ($\text{IL}-1$), and Interleukin-6 ($\text{IL}-6$)—acting synergistically with persistent elevations in cortisol, glucagon, and catecholamines.
• Uncontrolled Hepatic Gluconeogenesis: Cortisol and glucagon upregulate phosphoenolpyruvate carboxykinase (PEPCK), driving autonomous hepatic glucose production ($3\text{--}5\text{ mg/kg/min}$). Unlike simple fasting or starvation, this gluconeogenesis is completely unsuppressed by exogenous carbohydrate or intravenous insulin infusions.
• Accelerated Proteolysis: Cytokines and glucocorticoids activate the ATP-dependent ubiquitin-proteasome pathway in skeletal muscle. Somatic protein breakdown increases exponentially, releasing large quantities of branched-chain amino acids (BCAAs) for local oxidation, while alanine and glutamine are exported to the liver for gluconeogenesis and acute-phase protein synthesis (e.g., C-reactive protein, ferritin, fibrinogen) at the expense of visceral transport proteins (albumin, prealbumin, transferrin). Daily skeletal muscle losses can reach $1.0\text{ to }1.5\text{ kg}$ of lean tissue per day ($15\text{ to }25\text{ g}$ of urinary nitrogen loss daily).
• Insulin Resistance: Post-receptor signaling defects in skeletal muscle and adipose tissue suppress GLUT-4 transporter translocation, resulting in profound stress-induced hyperglycemia ($> 180\text{ mg/dL}$), which impairs neutrophil phagocytosis, elevates oxidative stress, and multiplies nosocomial infection rates.

3. The Recovery / Anabolic Phase

• Characterized by resolution of systemic inflammatory cascades, restoration of microvascular integrity, falling circulating counter-regulatory hormones, and normalization of blood glucose. Muscle catabolism ceases, and net nitrogen balance turns positive, permitting muscular hypertrophy and functional rehabilitation provided adequate substrate and physical therapy are supplied.

---

2016 SCCM/ASPEN Guidelines: Early Enteral Feeding

The Society of Critical Care Medicine (SCCM) and the American Society for Parenteral and Enteral Nutrition (ASPEN) guidelines mandate that enteral nutrition (EN) should be initiated within 24 to 48 hours of ICU admission in critically ill patients who cannot maintain oral intake, once hemodynamic stability has been achieved.

Physiological Mechanisms of Early Enteral Delivery

1. Preservation of Mucosal Architecture: Luminal nutrients provide direct fuel (butyrate, glutamine, ketone bodies) to enterocytes and colonocytes, stimulating brush-border blood flow, cell turnover, and preventing villous atrophy.
2. Maintenance of Tight Junctions: Luminal feeding prevents the breakdown of zonula occludens-1 (ZO-1) and occludin complexes, mitigating mucosal hyperpermeability ("leaky gut").
3. Support of GALT and MALT: Approximately $70\%$ of the body's immune cells reside in gut-associated lymphoid tissue (GALT). Luminal stimulation drives the synthesis and transcytosis of secretory Immunoglobulin A (sIgA), which neutralizes luminal pathogens and toxins.
4. Prevention of Bacterial Translocation: In the absence of luminal nutrients, intestinal bacteria adhere to mucosal surfaces and translocate across compromised epithelial barriers into mesenteric lymph nodes and portal circulation, igniting systemic inflammatory response syndrome (SIRS) and distant organ failure.

Enteral Versus Parenteral Nutrition in Critical Illness

Multiple randomized clinical trials (including the CALORIES and NUTRIREA-2 trials) have demonstrated similar mortality between EN and PN when caloric delivery is matched. However, enteral nutrition consistently demonstrates statistically significant reductions in infectious complications (line sepsis, intra-abdominal abscesses, nosocomial pneumonia) and hospital/ICU length of stay. Consequently, EN is the uncontested primary route of nutrition support in the ICU.

---

Nutrition Risk Screening in the ICU: NUTRIC and NRS-2002

Traditional nutrition markers such as serum albumin, prealbumin, and body weight are completely invalid in critical illness because they reflect acute-phase systemic inflammation and capillary leak rather than somatic nutrition reserves. SCCM/ASPEN guidelines mandate utilizing validated ICU-specific nutrition risk tools to stratify patients:

1. The NUTRIC Score (Nutrition Risk in Critically Ill)

The NUTRIC score was developed specifically for mechanically ventilated ICU patients to determine who will experience adverse clinical outcomes (mortality, prolonged ventilation) if nutrition is withheld.

• Risk Stratification:
  • Without IL-6: Score $\ge 5$ indicates High Nutritional Risk; score $0\text{--}4$ indicates Low Nutritional Risk.
  • With IL-6: Score $\ge 6$ indicates High Nutritional Risk; score $0\text{--}5$ indicates Low Nutritional Risk.
• Clinical Application: Patients at High Nutritional Risk derive substantial clinical benefit (reduced 28-day mortality) from rapid, aggressive attainment of target energy ($>80\%$ of calculated goal) and protein within 48 to 72 hours. Patients at Low Nutritional Risk tolerate trophic feeding or delayed feeding for up to 7 days without excess mortality.

2. NRS-2002 (Nutritional Risk Screening 2002)

A score of $\ge 5$ points (combining impaired nutritional status, severity of disease, and age $\ge 70$) classifies the patient as high risk, necessitating prompt nutritional intervention.

---

Trophic Feeding Versus Full Enteral Feeding in ARDS

In acute respiratory distress syndrome (ARDS) and acute lung injury (ALI), the gastrointestinal tract is vulnerable to hypoperfusion, while overfeeding risks excess carbon dioxide generation. The landmark EDEN Trial (Initial Trophic vs Full Enteral Feeding in Patients with Acute Lung Injury, Rice et al., JAMA 2012) addressed whether early full feeding is necessary.

• Trophic Feeding Definition: Delivering minimal volume enteral nutrition—typically $10\text{ to }20\text{ kcal/hr}$ or up to $500\text{ kcal/day}$ (approximately $10\text{ to }20\text{ mL/hr}$ of a standard $1.0\text{ kcal/mL}$ formula).
• Study Findings: Comparing initial trophic feeding for up to 6 days versus early full feeding advancing to goal within 48 hours demonstrated no significant differences in ventilator-free days (28 days), 60-day mortality, or infectious complications.
• Complication Rates: The full-feeding cohort suffered significantly higher rates of gastrointestinal intolerance, including elevated gastric residual volumes ($p < 0.001$), vomiting ($p < 0.001$), and diarrhea.
• Clinical Guideline Consensus: Trophic feeding was noninferior to early full feeding in the EDEN population and caused less gastrointestinal intolerance, but it is one acceptable strategy rather than a universal six-day mandate. The 2021 ASPEN guideline supports individualized delivery within about $12\text{ to }25\text{ kcal/kg/day}$ during the first 7 to 10 ICU days because trials have not shown a clear outcome advantage for forcing early goal energy.

---

Vasopressors, Shock, and Enteral Nutrition Safety

A critical exam topic is managing enteral nutrition in patients receiving vasoactive infusions. Vasopressors stimulate $\alpha_1$-adrenergic receptors, shunting arterial blood away from the splanchnic circulation to maintain coronary and cerebral perfusion. Introducing enteral formula into an ischemic bowel increases local oxygen demand, precipitating Non-Occlusive Mesenteric Ischemia (NOMI) and transmural gangrene, a complication carrying an $80\%$ mortality rate.

                      [ HEMODYNAMIC STABILITY CHECKLIST ]
                                       │
         ┌─────────────────────────────┴─────────────────────────────┐
         ▼                                                           ▼
[ ACTIVE / UNRESUSCITATED SHOCK ]                           [ STABLE / RESUSCITATED SHOCK ]
  • MAP < 65 mmHg                                             • MAP sustained >= 65 mmHg
  • Rapidly escalating vasopressors                           • Low, stable, or weaning pressors
  • Rising serum lactate / worsening base deficit             • Serum lactate normal or clearing
  • Peripheral hypoperfusion, oliguria                        • Warm extremities, adequate urine
         │                                                           │
         ▼                                                           ▼
[ HOLD ENTERAL NUTRITION ]                                  [ INITIATE CAUTIOUS TROPHIC EN ]
  • Strict NPO status                                         • Continuous infusion at 10–20 mL/hr
  • Bowel ischemia / NOMI risk extreme                        • Serial abdominal exams q4–6h
  • Resume only after hemodynamics stabilize                  • Stop if abdominal pain/distension/shock

Clinical Thresholds & ASPEN Recommendations

1. When to Withhold Enteral Nutrition:
   • Active, unresuscitated shock.
   • Mean Arterial Pressure (MAP) $< 65\text{ mmHg}$.
   • Rapidly escalating doses of vasopressors (e.g., steep upward titration of norepinephrine, epinephrine, or phenylephrine to sustain perfusion).
   • Rising serum lactate, severe base deficit, or clinical signs of mesenteric ischemia (abdominal rigidity, sudden ileus, high gastric residuals with bloody output).
2. When Enteral Nutrition is Safe to Initiate:
   • Fully fluid-resuscitated patient with a Mean Arterial Pressure sustained at $\ge 65\text{ mmHg}$.
   • Receiving low-dose, stable, or downtitrating vasopressors (e.g., norepinephrine $< 0.1\text{ to }0.14\text{ mcg/kg/min}$, or stable low-dose vasopressin $\le 0.03\text{ units/min}$ or phenylephrine).
   • Serum lactate is stable or downtrending.
   • Practice Rule: Start with trophic continuous infusion ($10\text{--}20\text{ mL/hr}$). Perform serial abdominal examinations every 4 to 6 hours. Immediately discontinue feeding if abdominal distension, localized tenderness, sudden increase in vasopressor requirement, or unexplained metabolic acidosis occurs.

---

Enteral Nutrition Delivery in Prone Positioning

Prone positioning for $16\text{ to }24\text{ hours daily}$ is an established evidence-based intervention that improves survival in severe ARDS ($P_{\text{aO}_2}/F_{\text{iO}_2} < 150\text{ mmHg}$). Many clinicians historically withheld enteral nutrition in the prone position due to fear of emesis, facial edema, and aspiration.

• Safety and Feasibility: Modern multicenter clinical trials (including PROSEVA) confirmed that enteral nutrition can be delivered safely in the prone position without increasing ventilator-associated pneumonia or aspiration events.
• Best Practice Protocol:
  • Position the bed in reverse Trendelenburg ($10\text{--}25^\circ$) with head elevation to reduce regurgitation risk.
  • Utilize continuous pump infusion; avoid bolus or gravity feedings.
  • Initiate prokinetic agents (metoclopramide $10\text{ mg}$ IV q6h or erythromycin $125\text{--}250\text{ mg}$ IV q8h) if gastric residual volumes are elevated or gastrointestinal dysmotility is suspected.
  • Place a post-pyloric (small bowel) feeding tube if gastric feeding intolerance persists despite prokinetics.

---

Immune-Modulating Nutrition: Arginine and Glutamine Controversies

Specialized enteral and parenteral formulations containing pharmacological doses of specific nutrients have undergone extensive clinical investigation. For board examinations, precise contraindications must be mastered:

1. Arginine in Severe Sepsis and Septic Shock

• Biochemical Pathway: L-Arginine serves as the sole substrate for nitric oxide synthases (NOS). In healthy tissue, endothelial NOS (eNOS) produces physiologic basal levels of nitric oxide ($NO$) to maintain microvascular blood flow.
• Mechanistic Concern in Sepsis: Inflammatory signaling can alter inducible nitric oxide synthase activity, creating a theoretical concern that pharmacologic arginine could worsen vasodilation in an unstable patient. Clinical trials have not established this mechanism as a universal cause of harm: $\text{L-Arginine} + \text{O}_2 + \text{NADPH} \xrightarrow{\text{iNOS}} \text{L-Citrulline} + \mathbf{NO} + \text{NADP}^+$
• Clinical Consequence: Overproduction of $NO$ triggers profound, refractory peripheral vasodilation, collapse of vascular smooth muscle tone, severe refractory hypotension, and increased mortality.
• Guideline Directive: SCCM/ASPEN guidance says immune-modulating formulas should not be used routinely in severe sepsis. This is a population-level recommendation based on inconsistent benefit, not proof that every exposure causes nitric-oxide-mediated collapse. Separately, enteral nutrition is held during refractory hypotension or escalating vasopressors regardless of formula.

2. Glutamine in Multi-Organ Dysfunction Syndrome (MODS)

• Historical Rationale: Glutamine is a conditionally essential amino acid during stress, serving as the primary fuel for enterocytes, colonocytes, and lymphocytes, while acting as a precursor for glutathione synthesis.
• The Landmark REDOXS Trial (Heyland et al., NEJM 2013): A rigorous, multicenter, randomized trial of 1,223 critically ill patients with multi-organ failure receiving high-dose enteral and parenteral glutamine (plus antioxidants). The trial demonstrated that glutamine supplementation was associated with a statistically significant INCREASE in 28-day mortality ($32.4\%$ vs. $27.2\%$) and 6-month mortality ($37.2\%$ vs. $31.0\%$), particularly in patients with acute kidney injury and multi-organ failure.
• Pathophysiological Mechanisms of Toxicity: Pharmacological doses overwhelmed damaged hepatic and renal urea clearance, causing severe hyperammonemia, accumulation of toxic glutamine metabolites, and cellular apoptosis in compromised parenchymal organs.
• Guideline Directive: SCCM and ASPEN guidelines explicitly state that routine enteral or parenteral glutamine supplementation should NOT be administered to critically ill patients with multi-organ dysfunction syndrome or shock.